在巴西霍奇金淋巴瘤登记处对HoLISTIC联盟晚期霍奇金淋巴瘤国际预后指数(A-HIPI)的外部验证与校准
本研究在巴西霍奇金淋巴瘤登记处中,对2022年开发的A-HIPI模型进行外部验证,该模型用于预测新诊断晚期经典型霍奇金淋巴瘤(cHL)患者的5年生存。共694例符合原始纳入标准(年龄18-65岁,IIB-IV期)的晚期cHL患者纳入分析,中位年龄31岁,46.3%为女性。5年无进展生存(PFS)和总生存(OS)分别为68.4%和86.0%。Harrell C统计量PFS为0.60、OS为0.69,Uno C统计量PFS为0.63、OS为0.72;校准图显示预测校准良好,5年OS和PFS的校准斜率分别为0.91和1.03。研究表明,尽管患者临床特征和社会经济因素存在差异,该基线预测工具在巴西队列中表现良好,具有足够的区分度和校准度,支持其在不同环境中的可靠性。
要点
- A-HIPI模型在巴西晚期cHL队列中5年PFS为68.4%,OS为86.0%。
- 区分度:Harrell C统计量PFS 0.60、OS 0.69;Uno C统计量PFS 0.63、OS 0.72。
- 校准斜率5年OS为0.91、PFS为1.03,校准图显示预测校准良好。
核心结论
- 尽管患者临床特征和社会经济因素存在差异,A-HIPI基线预测工具在巴西队列中表现良好,具有足够的区分度和校准度,支持其在不同环境中的可靠性。
研究设计与样本
- 本研究为外部验证与校准研究,使用巴西霍奇金淋巴瘤登记处数据。
- 截至2022年,登记处共纳入1357例cHL患者,中位随访5年。
- 共694例晚期cHL患者符合原始纳入标准(年龄18-65岁,IIB-IV期),纳入分析。
主要发现
- 中位年龄31岁,46.3%为女性;分期分布为IIB 33.1%、III 27.4%、IV 39.5%;大肿块病变占32.6%。
- 5年PFS为68.4%,5年OS为86.0%。
- Harrell C统计量PFS为0.60、OS为0.69;Uno C统计量PFS为0.63、OS为0.72。
- 校准图显示预测校准良好,5年OS校准斜率为0.91、PFS校准斜率为1.03。
关键数值与推荐
- A-HIPI模型预测新诊断晚期cHL患者5年生存。
- 允许范围外的实验室值被排除,与初始A-HIPI分析一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Hodgkin lymphoma International Study for Individual Care (HoLISTIC) Consortium's A-HIPI model, developed in 2022 for advanced-stage classical Hodgkin lymphoma (cHL), predicts survival within 5 years amongst newly diagnosed patients. This study validates its performance in the Brazilian Hodgkin lymphoma registry. By 2022, the Brazilian HL registry included 1357 cHL patients, with a median 5-year follow-up. Probabilities for 5-year progression-free survival (PFS) and overall survival (OS) were calculated using A-HIPI-model equations. Discrimination (Harrell C-statistic/Uno C-statistic) and calibration measures assessed external validation and calibration. Lab values beyond the allowed range were excluded, mirroring the initial A-HIPI analysis. A total of 694 advanced-stage cHL patients met the original inclusion criteria (age 18-65 years, Stage IIB-IV). Median age was 31 years; 46.3% were females. Stage distribution was IIB (33.1%), III (27.4%), IV (39.5%). Bulky disease in 32.6%. Five-year PFS and OS were 68.4% and 86.0%, respectively. Harrell C-statistics were 0.60 for PFS and 0.69 for OS, and Uno C-statistics were 0.63 for PFS and 0.72 for OS. Calibration plots demonstrated well-calibrated predictions with calibration slopes of 0.91 and 1.03 for 5-year OS and PFS, respectively. Despite differing patient, clinical characteristics, and socioeconomic factors, the baseline prediction tool performed well in the Brazilian cohort, demonstrating adequate discrimination and calibration. This supports its reliability in diverse settings.
引用
- Buccheri V, Moreira FR, Biasoli I, et al. External validation and calibration of the HoLISTIC Consortium's advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the Brazilian Hodgkin lymphoma registry. Br J Haematol. 2024. PMID: 39419492. doi:10.1111/bjh.19824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。